Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 86

1.

Elagolix suppresses ovulation in a dose-dependent manner: Results from a 3-month, randomized study in ovulatory women.

Archer DF, Ng J, Chwalisz K, Chiu YL, Feinberg EC, Miller CE, Feldman RA, Klein CE.

J Clin Endocrinol Metab. 2019 Oct 25. pii: dgz086. doi: 10.1210/clinem/dgz086. [Epub ahead of print]

PMID:
31650182
2.

Elagolix Pharmacokinetic Profiles in Women With Renal or Hepatic Impairment.

Ng J, Duan WR, Marbury T, Schmidt JM, Klein CE.

Clin Pharmacol Drug Dev. 2019 Nov;8(8):1053-1061. doi: 10.1002/cpdd.640. Epub 2018 Dec 20.

PMID:
30570832
3.

Population Pharmacokinetics of Elagolix in Healthy Women and Women with Endometriosis.

Winzenborg I, Nader A, Polepally AR, Liu M, Degner J, Klein CE, Mostafa NM, Noertersheuser P, Ng J.

Clin Pharmacokinet. 2018 Oct;57(10):1295-1306. doi: 10.1007/s40262-018-0629-6.

PMID:
29476499
4.

Methotrexate Dose in Patients With Early Rheumatoid Arthritis Impacts Methotrexate Polyglutamate Pharmacokinetics, Adalimumab Pharmacokinetics, and Efficacy: Pharmacokinetic and Exposure-response Analysis of the CONCERTO Trial.

Goss SL, Klein CE, Jin Z, Locke CS, Rodila RC, Kupper H, Burmester GR, Awni WM.

Clin Ther. 2018 Feb;40(2):309-319. doi: 10.1016/j.clinthera.2018.01.002.

PMID:
29402521
5.

Relationship Between Atrasentan Concentrations and Urinary Albumin to Creatinine Ratio in Western and Japanese Patients With Diabetic Nephropathy.

Lin CW, Mostafa NM, L Andress D, J Brennan J, Klein CE, Awni WM.

Clin Ther. 2018 Feb;40(2):242-251. doi: 10.1016/j.clinthera.2017.07.011. Epub 2017 Jul 27.

PMID:
28756065
6.

Dose-Dependent Suppression of Gonadotropins and Ovarian Hormones by Elagolix in Healthy Premenopausal Women.

Ng J, Chwalisz K, Carter DC, Klein CE.

J Clin Endocrinol Metab. 2017 May 1;102(5):1683-1691. doi: 10.1210/jc.2016-3845.

PMID:
28323948
7.

PALB2-Positive Breast Cancer in a 40-Year-Old Man.

Iyer P, Jasem J, Springer MA, Klein CE, Kabos P.

Oncology (Williston Park). 2017 Jan 15;31(1):50-2, 54. No abstract available.

8.

Pharmacokinetics and tolerability of paritaprevir, a direct acting antiviral agent for hepatitis C virus treatment, with and without ritonavir in healthy volunteers.

Menon RM, Klein CE, Podsadecki TJ, Chiu YL, Dutta S, Awni WM.

Br J Clin Pharmacol. 2016 May;81(5):929-40. doi: 10.1111/bcp.12873. Epub 2016 Feb 24.

9.

No Need for Lopinavir Dose Adjustment during Pregnancy: a Population Pharmacokinetic and Exposure-Response Analysis in Pregnant and Nonpregnant HIV-Infected Subjects.

Salem AH, Jones AK, Santini-Oliveira M, Taylor GP, Patterson KB, Nilius AM, Klein CE.

Antimicrob Agents Chemother. 2015 Nov 2;60(1):400-8. doi: 10.1128/AAC.01197-15. Print 2016 Jan.

10.

A novel ritonavir paediatric powder formulation is bioequivalent to ritonavir oral solution with a similar food effect.

Salem AH, Chiu YL, Valdes JM, Nilius AM, Klein CE.

Antivir Ther. 2015;20(4):425-32. doi: 10.3851/IMP2932. Epub 2015 Jan 9.

PMID:
25573904
11.

A Phase II trial of weekly bortezomib and dexamethasone in veterans with newly diagnosed multiple myeloma not eligible for or who deferred autologous stem cell transplantation.

Girnius SK, Lee S, Kambhampati S, Rose MG, Mohiuddin A, Houranieh A, Zimelman A, Grady T, Mehta P, Behler C, Hayes TG, Efebera YA, Prabhala RH, Han A, Yellapragada SV, Klein CE, Roodman GD, Lichtenstein A, Munshi NC.

Br J Haematol. 2015 Apr;169(1):36-43. doi: 10.1111/bjh.13243. Epub 2015 Jan 8.

PMID:
25572917
12.

Management of young breast cancer patients with de novo genetic mutations.

Fisher CM, Klein CE, Kondapalli LA, Elias AD, Borges VF.

Oncology (Williston Park). 2014 Oct;28(10):895-6. No abstract available.

13.

A food effect study and dose proportionality study to assess the pharmacokinetics and safety of bardoxolone methyl in healthy volunteers.

Teuscher NS, Kelley RJ, Dumas EO, Klein CE, Awni WM, Meyer CJ.

Clin Pharmacol Drug Dev. 2014 Jul;3(4):314-20. doi: 10.1002/cpdd.74. Epub 2013 Oct 22.

PMID:
27128838
14.

Exposure-clinical response analysis of paricalcitol in patients with chronic kidney disease (stage 5) on hemodialysis or peritoneal dialysis.

Noertersheuser PA, Pradhan RS, Klein CE, Williams LA, Palaparthy R, Garimella TS, Lichtenberger O, Awni WM.

J Clin Pharmacol. 2012 Aug;52(8):1162-73. doi: 10.1177/0091270011412966. Epub 2011 Sep 22.

PMID:
21940716
15.

Pharmacokinetics and safety of the lopinavir/ritonavir tablet 500/125 mg twice daily coadministered with efavirenz in healthy adult participants.

Ng J, Chiu YL, Awni W, Bernstein B, Causemaker SJ, Klein CE.

J Clin Pharmacol. 2012 Aug;52(8):1248-54. doi: 10.1177/0091270011410568. Epub 2011 Jun 30.

PMID:
21719718
16.

Diagnosis of invasive lobular carcinoma in a young woman presenting with pleomorphic lobular carcinoma in situ on core biopsy.

Kounalakis N, Diamond J, Rusthoven K, Horn W, Jindal S, Wisell J, Klein CE, Elias A, Finlayson C, Borges VF.

Oncology (Williston Park). 2011 Apr 15;25(4):351-6. No abstract available.

17.

Early-stage BRCA2-linked breast cancer diagnosed in the first trimester of pregnancy associated with a hypercoagulable state.

Diamond JR, Finlayson CA, Thienelt C, Kabos P, Hardesty L, Barbour L, Klein CE, Rabinovitch R, Elias A, Borges VF.

Oncology (Williston Park). 2009 Aug;23(9):784-91.

18.

A randomized phase II chemoprevention trial of 13-CIS retinoic acid with or without alpha tocopherol or observation in subjects at high risk for lung cancer.

Kelly K, Kittelson J, Franklin WA, Kennedy TC, Klein CE, Keith RL, Dempsey EC, Lewis M, Jackson MK, Hirsch FR, Bunn PA, Miller YE.

Cancer Prev Res (Phila). 2009 May;2(5):440-9. doi: 10.1158/1940-6207.CAPR-08-0136. Epub 2009 Apr 28.

19.

Cyclosporine therapy in dermatology.

Mrowietz U, Klein CE, Reich K, Rosenbach T, Ruzicka T, Sebastian M, Werfel T.

J Dtsch Dermatol Ges. 2009 May;7(5):474-9. doi: 10.1111/j.1610-0387.2009.07077.x. Epub 2009 Mar 19. Review. English, German. No abstract available.

PMID:
19302564
20.

Predictors of loss of virologic response in subjects who simplified to lopinavir/ritonavir monotherapy from lopinavir/ritonavir plus zidovudine/lamivudine.

Campo RE, Da Silva BA, Cotte L, Gathe JC, Gazzard B, Hicks CB, Klein CE, Chiu YL, King MS, Bernstein BM.

AIDS Res Hum Retroviruses. 2009 Mar;25(3):269-75. doi: 10.1089/aid.2008.0217.

PMID:
19292590
21.

Effects of acid-reducing agents on the pharmacokinetics of lopinavir/ritonavir and ritonavir-boosted atazanavir.

Klein CE, Chiu YL, Cai Y, Beck K, King KR, Causemaker SJ, Doan T, Esslinger HU, Podsadecki TJ, Hanna GJ.

J Clin Pharmacol. 2008 May;48(5):553-62. doi: 10.1177/0091270007313392.

PMID:
18440920
22.

High-dose lopinavir/ritonavir in highly treatment-experienced HIV-1 patients: efficacy, safety, and predictors of response.

Podzamczer D, King MS, Klein CE, Flexner C, Katlama C, Havlir DV, Letendre SL, Eron JJ, Brun SC, Bernstein B.

HIV Clin Trials. 2007 Jul-Aug;8(4):193-204.

PMID:
17720659
23.

Lack of effect of gastric acid-reducing agents on the pharmacokinetics of lopinavir/ritonavir in HIV-infected patients.

Chiu YL, Klein CE, Woodward WC, King KR, Naylor C, Awni W, Brun S.

AIDS Patient Care STDS. 2007 Apr;21(4):247-51.

PMID:
17461719
24.

The tablet formulation of lopinavir/ritonavir provides similar bioavailability to the soft-gelatin capsule formulation with less pharmacokinetic variability and diminished food effect.

Klein CE, Chiu YL, Awni W, Zhu T, Heuser RS, Doan T, Breitenbach J, Morris JB, Brun SC, Hanna GJ.

J Acquir Immune Defic Syndr. 2007 Apr 1;44(4):401-10.

PMID:
17224848
25.

Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers.

Yeh RF, Gaver VE, Patterson KB, Rezk NL, Baxter-Meheux F, Blake MJ, Eron JJ Jr, Klein CE, Rublein JC, Kashuba AD.

J Acquir Immune Defic Syndr. 2006 May;42(1):52-60.

PMID:
16639344
26.

Pharmacokinetics, pharmacodynamics and adherence to oral topotecan in myelodysplastic syndromes: a Cancer and Leukemia Group B study.

Klein CE, Kastrissios H, Miller AA, Hollis D, Yu D, Rosner GL, Grinblatt DL, Larson RA, Ratain MJ.

Cancer Chemother Pharmacol. 2006 Jan;57(2):199-206. Epub 2005 Sep 13.

PMID:
16158312
27.

Population pharmacokinetic model for irinotecan and two of its metabolites, SN-38 and SN-38 glucuronide.

Klein CE, Gupta E, Reid JM, Atherton PJ, Sloan JA, Pitot HC, Ratain MJ, Kastrissios H.

Clin Pharmacol Ther. 2002 Dec;72(6):638-47.

PMID:
12496745
28.

SWOG-9510: evaluation of topotecan in hormone refractory prostate cancer: a Southwest Oncology Group study.

Klein CE, Tangen CM, Braun TJ, Hussain MH, Peereboom DM, Nichols CR, Rivkin SE, Dakhil SR, Crawford ED.

Prostate. 2002 Sep 1;52(4):264-8.

PMID:
12210486
29.

A phase II trial of pyrazine diazohydroxide in patients with disseminated malignant melanoma and no prior chemotherapy--Southwest Oncology Group study.

Whitehead RP, Unger JM, Flaherty LE, Kraut EH, Mills GM, Klein CE, Chapman RA, Doolittle GC, Hammond N, Sondak VK; Southwest Oncology Group.

Invest New Drugs. 2002 Feb;20(1):105-11.

30.

Colorado family physicians' knowledge of hereditary breast cancer and related practice.

Mouchawar J, Klein CE, Mullineaux L.

J Cancer Educ. 2001 Spring;16(1):33-7.

PMID:
11270897
31.
32.

Phase I and pharmacokinetic study of irinotecan and docetaxel in patients with advanced solid tumors: preliminary evidence of clinical activity.

Adjei AA, Klein CE, Kastrissios H, Goldberg RM, Alberts SR, Pitot HC, Sloan JA, Reid JM, Hanson LJ, Atherton P, Rubin J, Erlichman C.

J Clin Oncol. 2000 Mar;18(5):1116-23.

PMID:
10694565
34.
35.

Hypoxia-induced up-regulation of angiogenin in human malignant melanoma.

Hartmann A, Kunz M, Köstlin S, Gillitzer R, Toksoy A, Bröcker EB, Klein CE.

Cancer Res. 1999 Apr 1;59(7):1578-83.

36.

Severe bullous drug reactions treated successfully with cyclophosphamide.

Trautmann A, Klein CE, Kämpgen E, Bröcker EB.

Br J Dermatol. 1998 Dec;139(6):1127-8. No abstract available.

PMID:
9990397
37.

Invasive behaviour of human gliomas is mediated by interindividually different integrin patterns.

Tonn JC, Wunderlich S, Kerkau S, Klein CE, Roosen K.

Anticancer Res. 1998 Jul-Aug;18(4A):2599-605.

PMID:
9703915
38.

Intravenous challenge with heparins in patients with delayed-type skin reactions after subcutaneous administration of the drug.

Trautmann A, Bröcker EB, Klein CE.

Contact Dermatitis. 1998 Jul;39(1):43-4. No abstract available.

PMID:
9686990
39.

Human mast cells augment fibroblast proliferation by heterotypic cell-cell adhesion and action of IL-4.

Trautmann A, Krohne G, Bröcker EB, Klein CE.

J Immunol. 1998 May 15;160(10):5053-7.

40.
41.
42.

Heterotypic cell-cell adhesion of human mast cells to fibroblasts.

Trautmann A, Feuerstein B, Ernst N, Bröcker EB, Klein CE.

Arch Dermatol Res. 1997 Mar;289(4):194-203.

PMID:
9143735
43.

ECM dependent and integrin mediated tumor cell migration of human glioma and melanoma cell lines under serum-free conditions.

Goldbrunner RH, Haugland HK, Klein CE, Kerkau S, Roosen K, Tonn JC.

Anticancer Res. 1996 Nov-Dec;16(6B):3679-87.

PMID:
9042241
44.

Patch testing in an unusual case of toxic epidermal necrolysis.

Klein CE, Trautmann A, Zillikens D, Bröcker EB.

Contact Dermatitis. 1996 Sep;35(3):175-6. No abstract available.

PMID:
8930481
45.
46.
47.

Loss of adhesion to basement membrane components but not to keratinocytes in proliferating melanocytes.

Danen EH, Jansen KF, Klein CE, Smit NP, Ruiter DJ, van Muijen GN.

Eur J Cell Biol. 1996 May;70(1):69-75.

PMID:
8738421
48.

Decreased expression of alpha 2 beta 1 integrin in scleroderma fibroblasts.

Kozlowska E, Sollberg S, Mauch C, Eckes B, Klein CE, Krieg T.

Exp Dermatol. 1996 Feb;5(1):57-63.

PMID:
8624613
49.

Increased expression of a 38kd cell-surface glycoprotein MH99 (KS 1/4) in oral mucosal dysplasias.

High AS, Robinson PA, Klein CE.

J Oral Pathol Med. 1996 Jan;25(1):10-3.

PMID:
8850351
50.

Patch testing in an unusual case of toxic epidermal necrolysis.

Klein CE, Trautmann A, Zillikens D, Bröcker EB.

Contact Dermatitis. 1995 Dec;33(6):448-9. No abstract available.

PMID:
8706422

Supplemental Content

Loading ...
Support Center